<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112263</url>
  </required_header>
  <id_info>
    <org_study_id>IEC/2021/000641</org_study_id>
    <nct_id>NCT05112263</nct_id>
  </id_info>
  <brief_title>Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis</brief_title>
  <acronym>TOCASU</acronym>
  <official_title>Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis: An Open Label Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised trial plans to compare oral tofacitinib with intravenous cyclosporine in&#xD;
      patients with acute severe ulcerative colitis who have failed to respond to intravenous&#xD;
      steroids&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>14 weeks</time_frame>
    <description>I) At Day 7 Absence of clinical response at day 7 (as defined by Partial Mayo of &gt; 3)&#xD;
II) By Day 98&#xD;
Relapse (Partial Mayo Score of 3 or more) between day 7 and day 98 requiring additional therapy&#xD;
Absence of steroid free remission at 14 weeks (Mayo &lt; 2 with MES 1 or less)&#xD;
Need for colectomy, third line medical rescue or biologics or mortality&#xD;
Serious adverse effect needing interruption of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>7 days</time_frame>
    <description>Partial Mayo &lt;4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of steroid free remission</measure>
    <time_frame>day 98</time_frame>
    <description>Mayo score of more than 2 with endoscopic sub-score of more than 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomy free survival</measure>
    <time_frame>98 days</time_frame>
    <description>No need for colectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical response</measure>
    <time_frame>98 days</time_frame>
    <description>Partial Mayo of 3 or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic healing</measure>
    <time_frame>Day 98</time_frame>
    <description>Mayo endoscopic sub-score of 1 or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse effects</measure>
    <time_frame>98 days</time_frame>
    <description>requiring hospitalization, cessation of treatment and events like cardiovascular events, pulmonary embolism, venous thrombosis, any infection, malignancy, gastrointestinal perforation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tofacitinib 10 mg TDS for 3 days, and then 10 mg BD to complete 8 weeks followed by 5 mg BD till follow-up (14 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients admitted with Acute severe ulcerative colitis as defined by Modified Truelove and&#xD;
        Witts Criteria WITH Failure to respond to intravenous steroids (Hydrocortisone 100 mg IV&#xD;
        QID OR IV Methylprednisolone 60 mg IV OD) as defined by&#xD;
&#xD;
          -  Day 3 non-response as per Oxford criteria (stool frequency of &gt; 8/day, OR stool&#xD;
             frequency between 3-8 with CRP &gt; 45 mg/L PLUS&#xD;
&#xD;
          -  Ongoing activity as defined by Partial Mayo Score of &gt; 3 (rectal bleeding sub-score of&#xD;
             &gt;1)&#xD;
&#xD;
          -  Decision to start second line therapy (within 5-7 days of starting intravenous&#xD;
             steroids)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18, Age &gt; 65 years&#xD;
&#xD;
               -  E1 disease (involvement distal to rectosigmoid junction only)&#xD;
&#xD;
               -  Crohn's disease&#xD;
&#xD;
               -  Contraindication to intravenous cyclosporine or oral tofacitinib&#xD;
&#xD;
                    -  Renal failure, uncontrolled hypertension, seizure disorder,and uncorrected&#xD;
                       hypomagnesemia (&lt;1.5 mg/L)&#xD;
&#xD;
                    -  Previous thrombosis, or prothrombotic state, on oral contraceptive, history&#xD;
                       of herpes zoster, active TB, active hepatitis, past opportunistic&#xD;
                       infections, h/o diverticulitis, Age &gt;50 plus at least one cardiac risk&#xD;
                       factor&#xD;
&#xD;
               -  Patient wants treatment with intravenous infliximab or wants surgery&#xD;
&#xD;
               -  Underlying sepsis or active infection (Enteric infections, Clostridium difficile,&#xD;
                  active hepatitis B or C, Tuberculosis, zoster, CMV disease)&#xD;
&#xD;
               -  Toxic megacolon, previous dysplasia or any indication of immediate surgery&#xD;
&#xD;
               -  Known malignancy&#xD;
&#xD;
               -  Pregnancy or Lactation&#xD;
&#xD;
               -  Unwilling to provide consent or for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vishal Sharma</last_name>
    <role>Principal Investigator</role>
    <affiliation>PGIMER Chandigarh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vineet Ahuja</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIIMS Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vishal Sharma</last_name>
    <phone>+917087008099</phone>
    <email>docvishalsharma@gmail.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Vishal Sharma</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The anonymised participant data may be shared on reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

